gt20029 | Kintor Advances With GT20029 Clinical Trials for Hair Loss

Keyword	CPC	PCC	Volume	Score	Length of keyword
gt20029	1.41	0.7	3286	1	7

Keyword	CPC	PCC	Volume	Score
gt20029	1.58	0.6	9155	30
gt20029 buy	0.57	0.9	6630	15
gt20029 reddit	0.38	0.3	9042	46
gt20029 release date	1.33	0.3	4168	4
gt20029 phase 2	0.44	0.6	7793	89
gt20029 grey market	0.67	0.8	4749	23
gt20029 e3	0.83	0.3	2888	28

Search Results related to gt20029 on Search Engine

Kintor Advances With GT20029 Clinical Trials for Hair Loss
hairscience.org

https://hairscience.org/news/gt20029-topical-androgen-degrader/

WebJun 14, 2023 · GT20029 is a new topical androgen receptor degrader medication developed by Kintor Pharmaceutical Ltd. for the treatment of pattern hair loss (androgenetic alopecia) and acne vulgaris. GT20029 successfully completed phase I clinical trials in men and women in China and the United States. Phase II clinical trials for this drug are now starting.

DA: 1 PA: 53 MOZ Rank: 39

GT20029 China Phase II Trial For AGA Reached Primary Endpoint
yahoo.com

https://finance.yahoo.com/news/gt20029-china-phase-ii-trial-015300252.html

Web1 day ago · The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of GT20029 for treating male AGA, and to determine ...

DA: 52 PA: 100 MOZ Rank: 2

GT20029 China Phase II Trial For AGA Reached Primary …
prnewswire.com

https://www.prnewswire.com/news-releases/gt20029-china-phase-ii-trial-for-aga-reached-primary-endpoint-302122889.html

Web1 day ago · The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of GT20029 for treating male AGA, and to determine ...

DA: 61 PA: 21 MOZ Rank: 99

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial …
prnewswire.com

https://www.prnewswire.com/news-releases/kintor-pharma-announces-positive-top-line-us-phase-i-trial-results-of-gt20029-the-worlds-first-topical-use-protac-compound-301743983.html

WebFeb 10, 2023 · GT20029 is a topical AR degrader developed by Kintor Pharma's PROTAC platform. The China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) cleared...

DA: 6 PA: 88 MOZ Rank: 71

Kintor Pharma’s GT20029 Phase II trial meets primary endpoint
clinicaltrialsarena.com

https://www.clinicaltrialsarena.com/news/kintor-trial-aga-treatment/

Web1 day ago · Kintor Pharma has announced that its GT20029 China Phase II trial in China has met the primary endpoint, showing significant results in treating male androgenetic alopecia (AGA). The trial evaluated the efficacy and safety of Kintor Pharma’s in-house developed first-in-class androgen receptor (AR) proteolysis targeting chimera (PROTAC ...

DA: 79 PA: 81 MOZ Rank: 41

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial …
kintor.com.cn

https://en.kintor.com.cn/news/235.html

WebGT20029 is a topical AR degrader developed by Kintor Pharma’s PROTAC platform. The China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively.

DA: 64 PA: 40 MOZ Rank: 54

Kintor Pharma Announces Dosing of First Subject in US Phase I …
prnewswire.com

https://www.prnewswire.com/news-releases/kintor-pharma-announces-dosing-of-first-subject-in-us-phase-i-clinical-trial-of-gt20029-for-androgenic-alopecia-and-acne-301474837.html

WebFeb 3, 2022 · GT20029 is an a topical androgenreceptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor...

DA: 52 PA: 52 MOZ Rank: 82

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial ... - BioSpace
biospace.com

https://www.biospace.com/article/releases/kintor-pharma-announces-positive-top-line-u-s-phase-i-trial-results-of-gt20029-the-world-s-first-topical-use-protac-compound/

WebFeb 10, 2023 · GT20029 is a topical AR degrader developed by Kintor Pharma's PROTAC platform. The China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively.

DA: 89 PA: 51 MOZ Rank: 13

Kintor reports positive data from trial of androgenetic alopecia
clinicaltrialsarena.com

https://www.clinicaltrialsarena.com/news/kintor-androgenetic-alopecia-therapy/

WebFeb 13, 2023 · Findings from the trial demonstrated that GT20029 was well tolerated, safe, and had good pharmacokinetic characteristics in healthy and AGA or acne subjects. It was also found to be well tolerated and safe in all cohorts at all dose levels.

DA: 21 PA: 40 MOZ Rank: 30

Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne …
practicaldermatology.com

https://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/

WebFeb 10, 2023 · GT20029 is a topical AR degrader developed by Kintor Pharma's PROTAC platform. The China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively.

DA: 29 PA: 74 MOZ Rank: 60